HIV-1-specific T cell immunity is considered to be crucial in the control of viral replication [5, 6] . It has been argued that the initiation of ART at a very early stage of infection, rather than later, might preserve HIV-1-specific CD4 + T cell responses and CD8 + T cell function and limit viral diversity and spreading in lymphoid tissue [7, 8] . However, ART alone may be insufficient, because continuous ART might reduce the antigenic stimulation of the HIV-1-specific CD8 + T cells and the antibodies that are necessary for maintaining functional immunity. Therefore, in patients with acute HIV-1 infection, a treatment strategy in which ART is supplemented with an immunogenic HIV-1 vaccine may represent the best chance for long-term virological control after interruption of ART [9] [10] [11] . Here, we describe the results of an international, randomized, doubleblind, placebo-controlled trial in which we tested the ability of 2 immunization regimens to induce virological control of HIV-1 24 weeks after discontinuation of ART in subjects who had initiated ART at the time of primary HIV-1 infection (PHI).
SUBJECTS, MATERIALS, AND METHODS
Study design. The QUEST study design has been described elsewhere (figure 1) [12] . Briefly, subjects initiated ART during PHI (р3 bands on Western blot), continued ART for у72 weeks, and had pVLs !50 HIV-1 RNA copies/mL 4 weeks before randomization. The majority of subjects ( ) initiated n p 69 Combivir, abacavir, and amprenavir. Ten subjects initiated ART containing 3 drugs. Subjects were divided among the following double-blind, placebo-controlled, randomized arms: arm A received ART, ALVAC-HIV (vCP1452) placebo, and Remune placebo; arm B received ART, ALVAC-HIV, and Remune placebo; and arm C received ART, ALVAC-HIV, and Remune. After a 20-week immunization period and 4 additional weeks of ART, subjects discontinued ART and were monitored for 24 weeks. Resumption of ART was advised for (1) severe clinical symptoms of acute retroviral syndrome with high pVL, (2) pVL 150,000 HIV-1 RNA copies/mL for 112 weeks, or (3) 150% CD4 + T cell count decline from the count measured before discontinuation of ART.
The random allocation sequence was generated by an independent GlaxoSmithKline statistician (who used an internal system with block size 6 and stratification by country) and was concealed from investigators. Sites received numbered containers with individual code-break envelopes. Data management was coordinated by the GlaxoSmithKline Biomedical Data Sciences Group (Oakville, Ontario).
Vaccines. ALVAC-HIV (vCP1452) (Sanofi pasteur) is a modified recombinant canarypox virus [13] . It expresses HIV-1 env (gp120 MN ) and gag (LAI) gene products and nef and pol gene products encompassing known human HLA-A2-restricted cytotoxic T cell (CTL) epitopes from these genes. Moreover, to enhance the overall efficiency of antigen expression, 2 vaccinia virus-derived genes, E3L and K3L, are included in the ALVAC genome. Remune is an inactivated envelope (gp120)-depleted whole virus immunogen in incomplete Freund's adjuvant (The Immune Response Corporation). Placebos were ALVAC-HIV placebo containing virus stabilizer and freeze-dried medium only and incomplete Freund's adjuvant [12] . Vaccines and/or placebos were administered intramuscularly every 4 weeks from randomization to week 20 while patients received ART ( figure 1) .
Outcome measures. The trial end points were (1) pVL р1000 HIV-1 RNA copies/mL at 24 weeks after discontinuation (and without resumption) of ART (primary end point), (2) pVL р400 HIV-1 RNA copies/mL throughout the 24-week period after discontinuation (and without resumption) of ART, and (3) time from discontinuation of ART to reach pVL 11000 HIV-1 RNA copies/mL. For end points 1 and 2, subjects who did not discontinue ART, resumed ART before week 24, or had missing data for pVL at week 24 were recorded as having treatment failure. For end point 3, subjects who did not discontinue ART were recorded as having treatment failure at time 0, and those who resumed ART were recorded as having treatment failure at the time ART was resumed. It was prespecified that the main analyses would compare end points between arm A and the combination of arms B and C using the intention-totreat principle.
Statistical analysis. Sample size was limited by logistical considerations, and we aimed at enrolling 75-90 subjects, which allowed for ∼80% power to detect a 30% difference between arms A and B/C for the primary end point. Proportions of successes according to end points 1 and 2 were compared between the 2 arms using the x 2 test (or Fisher's exact test), and 95% confidence intervals (CIs) for the difference in proportions were calculated using the Wilson method (Confidence Interval Analysis version 2.0; University of Southampton). Time from discontinuation of ART to pVL 11000 HIV-1 RNA copies/mL was compared between the 2 arms using the log-rank test, and the hazard ratio (HR) and 95% CI were calculated. Values of (and changes in) virological and immunological parameters were summarized by medians and ranges or interquartile ranges (IQRs) and were compared between arms using the Mann-Whitney U test. Correlations between parameters were assessed using Spearman's rank correlation coefficient. In these additional analyses, subjects who withdrew from the study or resumed ART had their week 24 values imputed using the last-observationcarried-forward principle, provided that this observation was у1 month after discontinuation of ART. Laboratory methods. Testing of safety parameters, pVL measurements (Amplicor Monitor; Roche Molecular Diagnostics), and CD4 + and CD8 + T cell counts (standard flow cytometry) were performed at central laboratories. Cell-associated HIV-1 DNA and RNA analyses was performed at the Laboratory of Virology, Geneva University Hospital (Geneva, Switzerland), as described elsewhere [14] .
Enzyme-linked immunospot (ELISPOT) assays. ELISPOT assay of HIV-1-specific interferon (IFN)-g-producing CD4
+ T cells was performed on fresh cells at 5 academic laboratories using a single operating procedure established at the central laboratory (Cellular Immunology Laboratory, Pitié-Salpetrière Hospital, Paris) and derived from a method described elsewhere [15] . Briefly, cells were cultured for 40 h with HIV-1 recombinant p24 (2 mg/mL; Protein-Science) to trigger HIV-1 p24-specific CD4 + T cells. Negative controls were obtained by culture with cells alone, and positive controls were obtained by culture with phytohemagglutinin (PHA; Abbott), streptokinase (Lederle), or crude extracts of cytomegalovirus (BioWittaker). After washings and the addition of biotinylated second-step anti-IFN-g monoclonal antibodies (Diaclone), spotforming cells (sfc) were counted per 10 6 peripheral blood mononuclear cells (PBMCs) using an ELISPOT reader (Zeiss). Background values (obtained by culture with cells alone) were subtracted from positive responses. Responses that were р100 sfc/10 6 PBMCs above background values were assigned a value of 0. Previous experiments confirmed that IFN-g production after HIV-1 p24 stimulation was due primarily to CD4 + T cells, because depletion of these cells resulted in an 85%-90% decrease in responses [16] .
ELISPOT assay of HIV-1-specific IFN-g-producing CD8 + T cells was performed at the central laboratory, as described elsewhere [15] . Available frozen samples were shipped to the central laboratory in liquid nitrogen (in a dry shipper from Air Liquide), and IFN-g-producing CD8
+ ELISPOT assays were performed in batches at the end of the study [15] . Cell samples with у80% viability when assessed by trypan blue staining were tested using the same procedure as described above, except that incubation was overnight and antigens consisted of 11 pools of 15-mer synthetic peptides spanning the entire HIV-1 gag sequence encoded by vCP1452, overlapping by 11 aa, and composed of 9-11 peptides/pool [15] . Negative and positive controls were obtained by culture with cells alone and PHA, respectively. The sum of responses to HIV-1 Gag was calculated after background values were subtracted, and responses р100 sfc/10 6 PBMCs above background values were assigned a value of 0. The origin of IFN-g-producing cells after stimulation with this peptide pool had been confirmed using the same technique on CD8-depleted PBMCs (85% decrease in responses) [16] . IFN-g-producing cells were also identified in 10 QUEST study samples that tested positive in response to these peptide pools in an intracellular cytokine assay [17] . These experiments confirmed that ∼80% of the IFN-g in peptide pool-stimulated PBMCs originated from CD8 + T cells. The primary measures of HIV-1-specific immunity were responses to HIV-1 p24, for CD4 + T cells, and to HIV-1 Gag, for CD8 + T cells, at week 24 after randomization.
Ethics. This study was conducted in accordance with the Declaration of Helsinki and Good Clinical Research Practice. All subjects provided signed, informed consent before enrollment. Independent local ethics committees and national gene therapy committees reviewed the protocol and its amendments. A data and safety monitoring board monitored the trial's progress. Clinicians, virologists, immunologists, and statisticians from Europe, Australia, and Canada formed the QUEST Core Group.
RESULTS

Subject recruitment and randomization.
Of 172 subjects screened from February 1998 to November 1999, 149 initiated ART containing 4 drugs, 1 of whom was subsequently found to be HIV negative and was excluded (figure 2). Seventy-nine subjects discontinued ART, withdrew before the randomization phase, or were not eligible for randomization. From August 2000 to February 2002, the remaining 69 subjects and 10 additional subjects who entered the study under protocol amendment 10 (Europe, ; Australia, ; and Canada, n n p 63 n p 13 p 3) were randomized to arms A ( ), B ( ), and n p 27 n p 26 C ( ). n p 26 Characteristics of randomized subjects. Demographic, immunological, and virological factors at randomization were similar in arms A and B/C (table 1). Of the 79 randomized subjects, 72 (91.1%) were male, 77 (97.5%) were white, and 57 (72.2%) were homosexual. At randomization, 49 subjects (62.0%) were receiving ART containing 3 drugs, and 30 subjects (38.0%) were receiving ART containing у4 drugs. In arm A, 13, 12, and 2 subjects were taking nucleoside reverse transcriptase inhibitors (NRTIs) only, NRTIs and protease inhibitors, or NRTIs and PBMCs). Four subjects had pVLs 150 HIV-1 RNA copies/mL (57, 90, 450, and 1067 HIV-1 RNA copies/mL). Subject follow-up and adherence to protocol. All 79 subjects completed the immunization schedule, and 78 of 79 discontinued ART at a median of 25 weeks (range, 23-51 weeks) after randomization. Six subjects had no pVL measurement at week 24 after discontinuation of ART. In addition, 7 subjects resumed ART before week 24, and 3 of them fulfilled the protocol guidelines for resuming ART. Therefore, 14 subjects (4 in arm A and 10 in arm B/C) were considered to have automatic treatment failure for end points 1 and 2 (figure 2).
Immunological and virological parameters during the immunization phase. There were no significant differences between arms A and B/C in CD4 + T cell count, pVL, or cellassociated HIV-1 RNA and DNA loads at week 24 after randomization or in changes in these parameters between randomization and week 24 ). Cell-associated HIV-1 RNA was P p .18 undetectable (!0.48 log HIV-1 RNA copy/10 6 PBMCs) in 54 (72.0%) of 75 subjects at randomization and in 35 (57.4%) of 61 subjects at week 24 after randomization (56.5% of subjects in arm A and 57.9% of subjects in arm B/C).
HIV-1-specific responses by ELISPOT assay at week 24 after randomization. CD4 + and CD8 + IFN-g ELISPOT data were available for 50 and 52 subjects, respectively. HIV-1-specific T cell responses were significantly higher in arm B/C than in arm Figure 3 . Percentage of subjects with plasma viral loads (pVLs) р1000 HIV-1 RNA copies/mL, by week from discontinuation of antiretroviral therapy (ART). Treatment failure was recorded for subjects who failed to discontinue ART, resumed ART, or had missing data. Arm A, ART, ALVAC-HIV (vCP1452) placebo, and Remune placebo; arm B, ART, ALVAC-HIV, and Remune placebo; arm C, ART, ALVAC-HIV, and Remune. ). Median time to pVL 11000 HIV-1 P p .27 RNA copies/mL (end point 3) was 29 days overall, and this was similar in arms A and B/C (28 and 29 days, respectively; HR 1.00 [95% CI, 0.61-1.64];
). P p .99 Other virological and immunological parameters after discontinuation of ART. The proportion of subjects with pVLs р1000 HIV-1 RNA copies/mL fell rapidly during the first 6 weeks after discontinuation of ART and remained relatively stable thereafter (figure 3). Table 2 shows that arms A and B/ C were similar with respect to pVL distribution at week 24 after discontinuation of ART. There were no significant differences between arms A and B/C in pVL, CD4 + T cell count, CD8 + T cell count, or cell-associated HIV-1 RNA and DNA loads at week 24 after discontinuation of ART or in changes in values before discontinuation to week 24 after discontinuation of ART ( Correlates of pVL at week 24 after discontinuation of ART. Although HIV-1-specific T cell responses, as measured by IFNg ELISPOT assay, were significantly higher in arm B/C than arm A after immunization, there was no significant correlation between these responses at week 24 after randomization and pVL at week 24 after discontinuation of ART for either CD4 + T cell response to HIV-1 p24 ( ; ; ) or n p 47 r p Ϫ0.03 P p .82 CD8 + T cell response to HIV-1 Gag ( ; ; n p 49 r p Ϫ0.04 ) (figure 4). In addition, there was no significant cor-P p .81 relation between pVL at week 24 after discontinuation of ART and CD4 + T cell count ( ; ; ), CD8 + T n p 76 r p 0.12 P p .30 cell count ( ; ; ), or cell-associated HIVn p 76 r p 0.04 P p .76 1 RNA load ( ; ; ) before discontinuan p 74 r p 0.07 P p .56 tion of ART, but a weak positive correlation was found with cell-associated HIV-1 DNA load before discontinuation of ART (n p 74; ; ). r p 0.26 P p .027 Adverse events during the immunization phase and after discontinuation of ART. In total, 9 (33%), 14 (54%), and 18 (69%) subjects in arms A, B, and C, respectively, had treatmentrelated adverse events (AEs). The most common AEs were reactions at the injection site (8, 7 , and 12 subjects in arms A, B, and C, respectively), musculoskeletal pain (2, 3, and 2 sub- Change from before discontinuation of ART 27 3. . Association between HIV-1-specific responses at week 24 after randomization and plasma viral load at week 24 after discontinuation of antiretroviral therapy (ART) in subjects with available samples (47 subjects for CD4 + T cell data and 49 subjects for CD8 + T cell data), using the lastobservation-carried-forward principle (if у1 month after discontinuation of ART) for subjects with missing week 24 values and those who resumed ART. Arm A, ART, ALVAC-HIV (vCP1452) placebo, and Remune placebo; arm B, ART, ALVAC-HIV, and Remune placebo; arm C, ART, ALVAC-HIV, and Remune; ELISPOT, enzyme-linked immunospot; sfc, spot-forming cells. jects), and fatigue (1, 3, and 3 subjects). There were no serious treatment-related AEs. No AE led to premature discontinuation of the vaccines or withdrawal from the study. No cases of severe acute retroviral syndrome or AIDS or a CD4 + T cell count !200 cells/mm 3 were noted during follow-up.
DISCUSSION
We report here the results of the first international, randomized, double-blind, placebo-controlled trial of therapeutic immunization in subjects who had initiated ART at the time of PHI. Adherence to the immunization regimen and planned discontinuation of ART was excellent. Overall, 17.7% of subjects had pVLs р1000 HIV-1 RNA copies/mL 24 weeks after discontinuation of ART. This proportion did not differ between the vaccine arms and the placebo arm. The upper bound of the 95% CI for the difference in proportions (10%) shows that the trial could rule out any substantial benefit of this immunization strategy for this end point in this clinical setting. There was no difference between the vaccine arms and the placebo arm in the time from discontinuation of ART to pVL 11000 HIV-1 RNA copies/mL or in median pVL at week 24 after discontinuation of ART. The use of a planned discontinuation of ART provided a means of assessing the potential for virological control by measuring the level of pVL after discontinuation of ART. We considered a 6-month period after discontinuation of ART to be sufficient to allow for the establishment of a stable viral set point. The safety of this strategy in our population was demonstrated by the absence of severe acute retroviral syndrome or progression to AIDS and high median CD4 + T cell counts. Similar strategies involving a planned interruption in ART have been selected for therapeutic immunization studies of chronically infected subjects, and time to resumption of ART was used as the primary end point [18, 19] .
The choice of vaccine candidates for this study was dictated by their safety records in HIV-1-infected subjects, immunogenicity, and availability [20] [21] [22] . Remune was used preferentially to increase CD4 + T helper cells, and ALVAC-HIV was used to increase CTLs [22] [23] [24] [25] . The combination of vaccines in a single treatment arm was selected for its potential to enhance both components of T cell immunity. Our results demonstrate that these vaccines were immunogenic, in that they increased CD4 + and CD8 + T cell responses, as measured by IFN-g ELISPOT assay, compared with the results with the placebo vaccines. However, the level of immunogenicity before discontinuation of ART was not correlated with pVL 6 months after discontinuation of ART. Our study was, therefore, not able to demonstrate a link between levels of HIV-1-specific T cell responses, as measured by IFN-g ELISPOT assay, and viremia. This is in contrast to findings from studies of animals, long-term nonprogressors (LTNPs) [16] , and subjects with acute and chronic HIV-1 infection [18, 19, [26] [27] [28] [29] [30] . A possible explanation for our results is that the immune responses induced by immunization were not of sufficient magnitude to affect viral replication after discontinuation of ART [5] . However, in a study of structured treatment interruptions during PHI, CD4 + and CD8 + T cell responses of similar intensity were found to be associated with virological control [31] .
When our results are compared with responses by LTNPs measured by the same ELISPOT assay, median levels of IFN-g production by CD8
+ T cells to HIV-1 Gag in our study were 10-fold below those observed in LTNPs, whereas CD4 + T cell responses to HIV-1 p24 did not differ [16] . Responses in LTNPs were further correlated with the pVL, the cell-associated HIV-1 DNA load, and an absence of disease progression [16] . Further emphasis may be needed not only on the number of IFN-gproducing cells but also on the type of immune function elicited for protection-such as the simultaneous production of interleukin-2 and IFN-g [16, 32, 33] , which may not have been elicited by the immunization procedure used in our study. Studies to characterize the kinetics of expansion, diversity, and differentiation of HIV-1-specific T cells in order to further investigate immunological correlates of virological control in our population are in progress. Ongoing follow-up of the QUEST cohort will assess the virological, immunological, and clinical effects of the immunization strategy over a longer period.
Because we aimed to enable virological control without ART, we chose what was considered to be the best clinical setting (i.e., PHI) and stringent virological end points. An association between pVL at set point and clinical prognosis has been demonstrated in previous studies [34] . However, our results should not preclude the use of other populations and end points in other assessments of this type of strategy. Our results may not be automatically applicable to chronically infected subjects. It remains unclear which of the 2 clinical settings is best suited for testing the efficacy of candidate immunogens.
In our study, 17.7% of all randomized subjects had pVLs р1000 HIV-1 RNA copies/mL at 6 months after discontinuation of ART. This raises the question of whether initiation of ART during PHI was beneficial in itself. This question cannot be directly evaluated by our study, because we did not include an ART-free control arm. There are no results from randomized, placebo-controlled trials of potent combination ART during PHI. Observational comparisons, although subject to bias, provide the only means available to address this issue. A comparison between the proportion of subjects with low pVLs after discontinuation of ART in our study population and the prevalence of low pVLs at a comparable time point after HIV seroconversion in untreated cohorts will be the subject of another study. Ultimately, results from randomized controlled trials are needed to provide definitive evidence of the effect that ART has during PHI [35] .
In conclusion, an overall 17.7% of our subjects who had initiated ART at the time of PHI fulfilled our primary end point of pVL р1000 HIV-1 copies/mL 24 weeks after discontinuation of ART. However, although the therapeutic immunization strategy we used was safe and immunogenic, we found no evidence that it increased the likelihood of low pVL after discontinuation of ART. Trials with designs and subject populations such as ours may be an appropriate means to evaluate immune-boosting agents and may contribute to the development of alternative strategies to long-term ART.
